臨床泌尿器科75巻13号

2021年12月発行

綜説

筋層非浸潤性膀胱癌（NMIBC）の再発と進展の予測

著者： 中村祐基¹ 藤井靖久¹

所属機関： ¹東京医科歯科大学大学院腎泌尿器外科学教室

ページ範囲：P.933 - P.940

文献概要

要旨

　初発膀胱癌の70％を占める筋層非浸潤性膀胱癌（NMIBC）は，経尿道的膀胱腫瘍切除術（TURBT）後にも高率かつ頻回に再発を繰り返し，一部の症例では進展を来す臨床的特徴をもつ．その再発や進展の抑制を目的とした治療指針を示すため，これまでさまざまなリスク分類が考案されてきた．現在頻用されているさまざまなリスク分類は主にTURBTの臨床的・病理学的因子や病歴に基づくものであるが，多様化し統一されていない点や，多くが欧米人のデータに基づくもので日本人の実情と合わない可能性がある点などの問題がある．本稿では，NMIBCのリスク分類について，これまで提唱されてきたリスク分類と現況，日本人におけるリスク分類，問題点と今後の展望について最近の文献をもとに解説する．

参考文献

1） Nishiyama H : Asia Consensus Statement on NCCN Clinical Practice Guideline for Bladder Cancer. Jpn J Clin Oncol 48 : 3-6, 2018

2） Antoni S, et al : Bladder Cancer Incidence and Mortality : A Global Overview and Recent Trends. Eur Urol 71 : 96-108, 2017

3） Sylvester RJ, et al : Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables : A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur Urol 49 : 466-477, 2006

4） Babjuk M, et al : European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer （Ta, T1, and Carcinoma in Situ）. Eur Urol, 2021 ［Online ahead of print］

5） Chang SS, et al : Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer : AUA/SUO Guideline. J Urol 196 : 1021-1029, 2016

6） Flaig TW, et al : Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Nat Compr Canc Netw 18 : 329-354, 2020

7） Fernandez-Gomez J, et al : Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated with Bacillus Calmette-Guerin : The CUETO Scoring Model. J Urol 182 : 2195-2203, 2009

8） Cambier S, et al : EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 69 : 60-69, 2016

9） Sylvester RJ, et al : European Association of Urology （EAU） Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer （NMIBC） Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade : An Update from the EAU NMIBC Guidelines Panel. Eur Urol 79 : 480-488, 2021

10） Balar AV, et al : Keynote 057 : Phase II Trial of Pembrolizumab （Pembro） for Patients （Pts） with High-Risk （HR） Nonmuscle Invasive Bladder Cancer （NMIBC） Unresponsive to Bacillus Calmette-Guérin （BCG）. J Clin Oncol 37 : 350, 2019

11） Balar AV, et al : Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG （KEYNOTE-057） : An Open-label, Single-arm, Multicentre, Phase 2 Study. Lancet Oncol 22 : 919-930, 2021

12） Kowalski M, et al : A phase II Study of Oportuzumab Monatox : An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin. J Urol 188 : 1712-1718, 2012

13） Boorjian SA, et al : Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer : A Single-arm, Open-label, Repeat-dose Clinical Trial. Lancet Oncol 22 : 107-117, 2021

14） Fernandez-Gomez J, et al : The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin : External Validation of the EORTC Risk Tables. Eur Urol 60 : 423-430, 2011

15） Hernández V, et al : External Validation and Applicability of the EORTC Risk Tables for Non-muscle-invasive Bladder Cancer. World J Urol 29 : 409-414, 2011

16） Xylinas E, et al : Accuracy of the EORTC Risk Tables and of the CUETO Scoring Model to Predict Outcomes in Non-muscle-invasive Urothelial Carcinoma of the Bladder. Br J Cancer 109 : 1460-1466, 2013

17） Humphrey PA, et al : The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B : Prostate and Bladder Tumours. Eur Urol 70 : 106-119, 2016

18） Fujii Y, et al : Significance of Bladder Neck Involvement on Progression in Superficial Bladder Cancer. Eur Urol 33 : 464-468, 1998

19） Kobayashi S, et al : Impact of Bladder Neck Involvement on Progression in Patients with Primary Non-Muscle Invasive Bladder Cancer : A Prospective Validation Study. Urol Oncol 32 : 38.e29-36, 2014

20） Fujii Y : Prediction Models for Progression of Non-muscle-invasive Bladder Cancer : A Review. Int J Urol 25 : 212-218, 2018

21） Waseda Y, et al : Impact of Bladder Neck Involvement on Recurrence in Patients with Non-muscle-invasive Bladder Cancer : An Analysis Based on a Time-dependent Model. Clin Genitourin Cancer 18 : e62-e70, 2020

22） Fukushima H, et al : Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer. Eur Urol Focus 7 : 366-372, 2021

23） Sakano S, et al : Risk Group Stratification to Predict Recurrence After Transurethral Resection in Japanese Patients with Stage Ta and T1 Bladder Tumours : Validation Study on the European Association of Urology Guidelines. BJU Int 107 : 1598-1604, 2011

24） Ieda T, et al : Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia. EBioMedicine 12 : 98-104, 2016

25） Miyake M, et al : A New Risk Stratification Model for Intravesical Recurrence, Disease Progression, and Cancer-Specific Death in Patients with Non-Muscle Invasive Bladder Cancer : The J-NICE Risk Tables. Int J Clin Oncol 25 : 1364-1376, 2020

26） Kikuchi E, et al : Clinical Outcome of Tumor Recurrence for Ta, T1 Non-Muscle Invasive Bladder Cancer from the Data on Registered Bladder Cancer Patients in Japan : 1999-2001 Report from the Japanese Urological Association. Int J Urol 16 : 279-286, 2009

27） Afferi L, et al : Biomarkers Predicting Oncological Outcomes of High-Risk Non-Muscle-Invasive Bladder Cancer. Minerva Urol e Nefrol 72 : 265-278, 2020

28） van Rhijn BW, et al : Molecular Grade （FGFR3/MIB-1） and EORTC Risk Scores Are Predictive in Primary Non-muscle-invasive Bladder Cancer. Eur Urol 58 : 433-441, 2010

29） Kardoust Parizi M, et al : Fibroblast Growth Factor Receptor : A Systematic Review and Meta-analysis of Prognostic Value and Therapeutic Options in Patients with Urothelial Bladder Carcinoma. Urol Oncol 39 : 409-421, 2021

30） Yuan X, et al : The Genetic Difference Between Western and Chinese Urothelial Cell Carcinomas : Infrequent FGFR3 Mutation in Han Chinese Patients. Oncotarget 7 : 25826-25835, 2016

31） Shariat SF, et al : Nomograms Including Nuclear Matrix Protein 22 for Prediction of Disease Recurrence and Progression in Patients with Ta, T1 or CIS Transitional Cell Carcinoma of the Bladder. J Urol 173 : 1518-1525, 2005

32） Bertz S, et al : Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer. Eur Urol 65 : 218-226, 2014

33） Gazzaniga P, et al : Circulating Tumor Cells Detection Has Independent Prognostic Impact in High-risk Non-muscle Invasive Bladder Cancer. Int J Cancer 135 : 1978-1982, 2014